^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | pictilisib (GDC-0941) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD10-06 Clinical outcomes and exploratory gene expression analysis of OPPORTUNE: a phase II window-of-opportunity study to evaluate pictilisib+anastrozole versus anastrozole alone in ER-positive breast cancer
Published date:
11/22/2022
Excerpt:
Postmenopausal women with newly diagnosed operable ER+/HER2-negative BC were randomly allocated...preoperative treatment with ANA 1 mg once per day (n= 47) or the combination of ANA 1 mg with PIC 260 mg once per day (n = 89)....PIC exhibited greater antiproliferative effects in combination with ANA in ER+/HER2- early BC compared to ANA alone...
Secondary therapy:
anastrozole
